U.S., Sept. 30 -- ClinicalTrials.gov registry received information related to the study (NCT07197671) titled 'Y-NM600 in Patients Receiving Anti-PD-1 or Anti-PD-L1 for Metastatic Cancer' on Sept. 15.
Brief Summary: Participants with metastatic cancer who are taking anti-PD-1 or anti-PD-L1 therapy will be enrolled to assess the safety of and find the optimal dose for radioactive imaging agents and to explore whether these agents will make current drug therapies work better. Up to 60 participants will be enrolled and can expect to be on study for up to 9 months.
Study Start Date: Nov., 2025
Study Type: INTERVENTIONAL
Condition:
Metastatic Cancer
Intervention:
DRUG: 90Y-NM600
NM600 is a tumor-selective, pan-cancer, targeted radionuclid...